The DNM3 antibody targets dynamin-3 (DNM3), a member of the dynamin family of GTPases involved in membrane remodeling processes such as endocytosis, vesicle trafficking, and cytoskeletal regulation. Dynamin-3. encoded by the DNM3 gene, is expressed predominantly in the brain, particularly in neurons, where it plays roles in synaptic vesicle recycling, receptor internalization, and structural plasticity. Unlike dynamin-1 (neuronal-specific) and dynamin-2 (ubiquitous), DNM3's functions are less well-characterized but are implicated in neural development, learning, and memory. DNM3 antibodies are essential tools for studying its expression, localization, and interaction partners in cellular and tissue contexts. They are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore DNM3's involvement in neurological disorders, including Alzheimer's disease, Huntington's disease, and schizophrenia, as well as cancers where DNM3 dysregulation has been observed. Research also links DNM3 to tumor invasiveness and chemoresistance, highlighting its potential as a therapeutic target. Validated DNM3 antibodies help clarify its tissue-specific roles and mechanisms, advancing understanding of cellular trafficking pathways and disease pathogenesis.